The results of the ZEST randomized controlled trial presented on March 29th at the American College of Cardiology (ACC) 2009 showed that the CYPHER Stent significantly outperformed the ENDEAVOR Stent and the TAXUS LIBERTE Stent in the key clinical outcomes of ischemia-driven target lesion revascularization (TLR) and stent thrombosis through one year. The rates of ischemia-driven TLR and target vessel revascularization (TVR) were lowest in the CYPHER Stent group compared to the ENDEAVOR Stent arm (TLR=1.4 percent vs. 4.9 percent; p